~~<i id='33C54571B8'><strike id='33C54571B8'><tt id='33C54571B8'><pre id='33C54571B8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：Wikipedia 2025-09-27 12:22:46 - browse：88

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： It's been 20 years since Dolly the sheep. Where's my clone?

hotspot

Wikipedia

explore

knowledge

focus

AvialofPfizer’snewvaccinetoprotectinfantsagainstrespiratorysyncytialvirus.CourtesyPfizerPfizer’snews

WSS

Ukraine and a new approach to mental health in war

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Can food be medicine? And other questions about a new push

Australia's humpback populations rebound raising hopes of marine scientists

Community addresses injustice for Long Island mothers

knowledge

entertainment

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Experts study whether long Covid risk adds up with each reinfection

Bright Health sells Medicare Advantage business to Molina

Brain 'hot spot' may explain why African Americans feel greater pain

Walensky prepares to leave CDC — and Congress — behind

Medical student insurance fails on mental health care coverage

Heart attack and stroke risk calculators need revising

Why is France rioting? What to know about the fatal police shooting of Nahel M

New air purifier tech could be key to improving indoor air quality

Biotech stock slump in 2023: awaiting the turnaround

Wikipedia

How AI helped researchers track recovery from depression

Changes to biosimilar regulatory framework must prioritize patients

CommonSpirit Health keeps growing, even as it loses money

Medical student insurance fails on mental health care coverage

New case study details death in closely watched Alzhiemer's trial

Biotech stock slump in 2023: awaiting the turnaround

explore

explore

knowledge

focus